Company Overview of Wyeth LLC
Wyeth LLC develops, manufactures, distributes, and markets pharmaceutical products the United States, the United Kingdom, and internationally. The company’s Pharmaceuticals segment offers neuroscience therapies, vaccines, musculoskeletal therapies, nutritional products, gastroenterology drugs, anti-infectives, oncology therapies, hemophilia treatments, immunological products, and women's healthcare products. It offers its products to wholesalers, pharmacies, hospitals, governments, physicians, retailers, and other human healthcare institutions. The company's Consumer Healthcare segment develops, manufactures, distributes, and markets over-the-counter healthcare products comprising analgesics...
235 East 42nd Street
New York, NY 10017-5703
Founded in 1926
Key Executives for Wyeth LLC
Chief Counsel and Senior Vice President
Executive Vice President of Technical Operations and Product Supply Operational Excellence
Principal Corporate Officer and Vice President of Internal Audit
Vice President of Taxes and Member of Finance and Retirement Committees
Compensation as of Fiscal Year 2016.
Wyeth LLC Key Developments
Catalyst Biosciences, Inc. Completes Manufacturing Agreements for its Novel Factor VIIa Product, Marzeptacog alpha (activated)
Dec 19 16
Catalyst Biosciences Inc. announced it has secured all rights to the manufacturing process for marzeptacog alfa (activated) (formerly known as CB 813d) from Wyeth LLC, a wholly-owned subsidiary of Pfizer. Marzeptacog alfa (activated) is a next-generation Factor VIIa product that was designed to allow for the effective, long-term, subcutaneous prophylaxis in hemophilia patients with inhibitors. Catalyst has successfully completed an intravenous Phase 1 clinical trial of marzeptacog alfa (activated) in patients with severe hemophilia A and B with and without inhibitors and has demonstrated the feasibility of subcutaneous dosing in preclinical models. In addition, the company announced that it has signed a drug product fill-finish manufacturing services agreement with Symbiosis Pharmaceutical Services Limited for marzeptacog alfa (activated) for clinical trial applications. This agreement, and the previously announced drug substance manufacturing agreement with CMC Biologics, provides Catalyst Biosciences with complete manufacturing capabilities to enable cGMP manufacturing of marzeptacog alfa (activated).
Catalyst Biosciences, Inc. Enters into Research and License Agreement with Wyeth LLC
Dec 14 16
On December 8, 2016, Catalyst Biosciences Inc. entered into a definitive agreement with Wyeth LLC (Wyeth) following the June 1, 2015 termination of the research and license agreement that was entered into on June 29, 2009 between the company and Wyeth to collaborate on the development of novel human Factor VIIa products. Pursuant to the agreement, Wyeth has granted the company an exclusive license to Wyeth's proprietary rights that apply to Factor VIIa variants, CB 813a and CB 813d, to research, develop, manufacture and commercialize the Products. Wyeth has also transferred and will transfer to the company documentation related to the development, manufacturing and testing of the Products, including the Investigational New Drug application. In connection with the license granted by Wyeth to the company, the company agreed to make contingent cash payments to Wyeth in an aggregate amount equal to up to $17.5 million, payable upon the achievement of clinical, regulatory and commercial milestones. Following commercialization of any Product, Wyeth would also receive a single-digit royalty on net Product sales on a country-by-country basis for a predefined royalty term.
Wyeth Reaches Agreement in Principle to Resolve Medicaid Drug Rebate Claims for 2001-2006 Period for Protonix
Feb 16 16
Pfizer Inc. reported that its Wyeth subsidiary has reached an agreement in principle to resolve claims alleging that Wyeth's practices relating to the calculation of Medicaid rebates for its drug Protonix (pantoprazole sodium) between 2001 and 2006, several years before Pfizer acquired Wyeth in 2009, violated the Federal Civil False Claims Act and other laws. When finalized, the agreement in principle is expected to fully resolve cases pending in Federal District Court for the District of Massachusetts before the Honorable Douglas P. Woodlock. Under the agreement in principle, Wyeth will make a payment of $784.6 million to resolve these claims. The agreement in principle does not include an admission of liability by Wyeth. The resolution is subject to the negotiation of final settlement agreements and court approval.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|